GlassScriptPhysician profile
Sandeep Grewal
NPI 1932315124
$2,569.72
in general payments reported to CMS, 2019-2025
41 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $696 · 2021: $540 · 2022: $43.80 · 2023: $53.39 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $153.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $244.47 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.63 | 2019-2021 | |
| Amgen INC. | $185.64 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $133.84 | 2019-2021 | |
| Exelixis INC. | $129.56 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $121.21 | 2019-2021 | |
| Eisai INC. | $116.12 | 2019 | |
| Genentech USA, INC. | $102.12 | 2019-2020 | |
| Kite Pharma, INC. | $101.01 | 2020 | |
| Celgene Corporation | $94.37 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.13 | 2019-2023 | Abilify |
| Novartis Pharmaceuticals Corporation | $77.13 | 2019-2020 | |
| Taiho Oncology, INC. | $60.69 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $57.90 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.